Among 141 HIV–HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy. Seven patients showed a delayed response to tenofovir. The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of HBV genomes directly isolated from patients’ sera.
Methods
After purification of DNA from serum samples, full-length HBV DNA was amplified by PCR, cloned and sequenced. Drug sensitivity of HBV strains isolated from four delayed responders and five good-responders was assessed and compared to a wild-type HBV strain after transfection of the full genome into HepG2 cells.
Results
Delayed responders, compared with good responders, showed a higher incidence of lamivudine-resistant mutations (71% and 35%, respectively; P=0.021) and a higher proportion of HBV genotype G (57% versus 16%, respectively; P=0.026). Clonal analysis demonstrated a higher variability of HBV quasispecies in delayed reponders than in good responders. In vitro analysis showed a lower efficacy of adefovir and tenofovir in delayed reponders. Furthermore, HBV genotype G strains showed a mild to weak susceptibility to tenofovir.
Conclusions
The reason for the slow decline in HBV DNA level observed during therapy in delayed responders is not clear. Delayed responders showed higher quasispecies variability, a higher proportion of HBV genotype G and a mild in vitro decreased susceptibility to tenofovir and adefovir. A combination of these factors in heavily treatment-experienced HIV-infected patients could explain the lower tenofovir activity. These patients must be closely monitored to prevent prospective emergence of resistance to approved antiviral drugs.
References
1.
SulkowskiM.S.Viral hepatitis and HIV coinfection. J Hepatol2008; 48: 353–367.
2.
Di MartinoV., ThevenotT., ColinJ.F.Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology2002; 123: 1812–1822.
3.
SorianoV., PuotiM., BonaciniM.Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS2005; 19: 221–240.
4.
LaiC.L., ChienR.N., LeungN.W.A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med1998; 339: 61–68.
5.
BenhamouY., BochetM., ThibaultV.Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology1999; 30: 1302–1306.
6.
DasK., XiongX., YangH.Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol2001; 75: 4771–4779.
7.
YatsujiH., NoguchiC., HiragaN.Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother2006; 50: 3867–3874.
8.
LimS.G., KrastevZ., NgT.M.Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother2006; 50: 1642–1648.
9.
De ClercqE., SakumaT., BabaM.Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res1987; 8: 261–272.
10.
YingC., De ClercqE., NicholsonW., FurmanP., NeytsJ.Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat2000; 7: 161–165.
11.
BenhamouY., FleuryH., TrimouletP.Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology2006; 43: 548–555.
12.
MatthewsG.V., AvihingsanonA., LewinS.R.A randomized trial of combination hepatitis B therapy in HIV/ HBV coinfected antiretroviral naive individuals in Thailand. Hepatology2008; 48: 1062–1069.
13.
YangH., QiX., SabogalA.Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther2005; 10: 625–633.
14.
HammerS.M., EronJ.J.Jr., ReissP.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel. JAMA2008; 300: 555–570.
15.
LadaO., BenhamouY., CahourA.In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther2004; 9: 353–363.
16.
GüntherS., LiB.C., MiskaS.A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol1995; 69: 5437–5444.
17.
PasS.D., FriesE., De ManR.A., OsterhausA.D., NiestersH.G.Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol2000; 38: 2897–2901.
18.
PeytavinG., GautranC., OtoulC.Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. Eur J Clin Pharmacol2005; 61: 267–273.
19.
NainanO.V., KhristovaM.L., ByunK.Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol2002; 68: 319–327.
20.
MarcellinP., HeathcoteE.J., ButiM.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med2008; 359: 2442–2455.
21.
PetersM.G., AndersenJ., LynchP.Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology2006; 44: 1110–1116.
22.
LacombeK., GozlanJ., BoydA.Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. Antivir Ther2008; 13: 705–713.
23.
NúñezM., Perez-OlmedaM., DiazB.Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS2002; 16: 2352–2354.
24.
DoreG.J., CooperD.A., PozniakA.L.Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis2004; 189: 1185–1192.
25.
LacombeK., GozlanJ., BoydA.HBV blippers and rebounders under treatment with tenofovir in HIV/ HBV co-infection.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada, 2009.
26.
SheldonJ., CaminoN., RodesB.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther2005; 10: 727–734.
27.
SchmutzG., NelsonM., LutzT.Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS2006; 20: 1951–1954.
28.
TanJ., DegertekinB., WongS.N.Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol2008; 48: 391–398.
29.
FungS.K., MazzulliT., ShermanM., PopovicV., SablonS.Presence of rtA194T at baseline does not reduce efficacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B. Hepatology2008; 48Suppl 1: 699A.
30.
OsiowyC., GordonD., BorlangJ., GilesE., VilleneuveJ.P.Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. J Gen Virol2008; 89: 3009–3015.
31.
LacombeK., MassariV., GirardP.M.Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS2006; 20: 419–427.
32.
KatoH., OritoE., GishR.G.Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology2002; 35: 922–929.
33.
StuyverL., De GendtS., Van GeytC.A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol2000; 81: 67–74.
34.
ChudyM., SchmidtM., CzudaiV.Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology2006; 44: 99–107.
35.
ZhuY., CurtisM., Snow-LampartA.In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations. J Clin Microbiol2007; 45: 3335–3341.
36.
AudsleyJ., ArrifinN., YuenL.Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Med2009; 10: 229–235.
37.
BrunelleM.N., JacquardA.C., PichoudC.Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology2005; 41: 1391–1398.
38.
LocarniniS., WarnerN.The multi-drug resistant HBV RTA 181T has a secretion defect and significantly reduces the kinetics of viral rebound. Hepatology2007; 46: 654A.
European Association For The Study Of The Liver.EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol2009; 50: 227–242.
41.
LaiC.L., GaneE., LiawY.F.Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med2007; 357: 2576–2588.
42.
LamperticoP., ViganoM., ManentiE.Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology2007; 133: 1445–1451.
